We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.
- Recent MRNA Stock Price: $197.02
- Yearly Gain for MRNA stock: 2.19%
- Market Cap for MRNA stock: $73.26B
- P/E Ratio for MRNA stock: 6.895
Will MRNA's stock price go up? Is there an accurate MRNA stock forecast available?
TipRanks.com reports that Moderna currently has 15 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $219.92. The target pricing ranges from a high MRNA forecast of $506.00 down to a low forecast of $111.00. Moderna (MRNA)’s last closing stock price was $197.02 which would put the average price target at 11.62% upside.
In addition, TradingView issued a Strong Buy rating for MRNA stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MRNA stock.
Other analysts covering MRNA include:
- Michael Yee of Jefferies issued a Buy rating with the price target of $ 275 on 1 day ago
- Leah R. Cann of Brookline Capital Markets issued a Buy rating with the price target of $ 506 on 1 day ago
- Mani Foroohar of SVB Securities issued a Hold rating with the price target of $ 111 on 1 day ago
If you are wondering if MRNA is a good stock to buy, here are 3rd party ratings for MRNA stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 28% (70 out of 251)
What is the sentiment on the street regarding Moderna? (Current ratings compiled by TipRanks.com)
- News Sentiment for MRNA stock: Very Bullish
- Blogger Consensus for MRNA stock: Bullish
- Media Buzz for MRNA stock: Medium
- Insider Signal for MRNA stock: Negative
- Investor Sentiment for MRNA stock: n/a
- Hedge Fund signal for MRNA stock: Negative
The stock market is extremely volatile, and you need to do your own research on MRNA stock including scouring the social networks like MRNA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MRNA stock chart >>
Summary: Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California.
- Recent NTRA Stock Price: $40.98
- Yearly Gain for NTRA stock: -34.51%
- Market Cap for NTRA stock: $4.36B
- P/E Ratio for NTRA stock: -7.033
Will NTRA's stock price go up? Is there an accurate NTRA stock forecast available?
TipRanks.com reports that Natera currently has 9 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $63.00. The target pricing ranges from a high NTRA forecast of $90.00 down to a low forecast of $28.00. Natera (NTRA)’s last closing stock price was $40.98 which would put the average price target at 53.73% upside.
In addition, TradingView issued a Buy rating for NTRA stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on NTRA stock.
Other analysts covering NTRA include:
- David Westenberg of Piper Sandler issued a Buy rating with the price target of $ 70 on 1 day ago
- Julia Qin of J.P. Morgan issued a Buy rating with the price target of $ 90 on 1 month ago
If you are wondering if NTRA is a good stock to buy, here are 3rd party ratings for NTRA stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Bottom 37% (157 out of 251)
What is the sentiment on the street regarding Natera? (Current ratings compiled by TipRanks.com)
- News Sentiment for NTRA stock: Bullish
- Blogger Consensus for NTRA stock: Neutral
- Media Buzz for NTRA stock: Very High
- Insider Signal for NTRA stock: Positive
- Investor Sentiment for NTRA stock: n/a
- Hedge Fund signal for NTRA stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on NTRA stock including scouring the social networks like NTRA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for NTRA stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================